FDA Progestins Classification and Pharmacology

The FDA has released a document concerning the classification and pharmacology of progestins, identified by the docket number FDA-2026-P-2641-0012. This guidance is intended to provide clarity on the categorization and scientific understanding of progestin compounds.

While this document appears to be informational guidance, regulated entities such as drug manufacturers and pharmaceutical companies should review it to ensure their understanding aligns with the FDA's current perspectives on progestin classification and pharmacology. No immediate compliance actions or deadlines are specified, but adherence to FDA guidance is generally expected.